<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240417141106&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240417141106&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 17 Apr 2024 18:11:07 +0000</lastbuilddate>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Man in His Sixth Decade of Life With Totally Occluded Abdominal Aorta (Leriche Syndrome)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630495/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 17. doi: 10.1001/jamacardio.2024.0530. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630495/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38630495</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0530>10.1001/jamacardio.2024.0530</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630495</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Karley Fischer</dc:creator>
<dc:creator>Zuha Nazir</dc:creator>
<dc:creator>Damian Valencia</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Man in His Sixth Decade of Life With Totally Occluded Abdominal Aorta (Leriche Syndrome)</dc:title>
<dc:identifier>pmid:38630495</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0530</dc:identifier>
</item>
<item>
<title>Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630494/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this post hoc analysis of the REDUCE LAP-HF II trial, over 2 years of follow-up, atrial shunting led to reverse remodeling of left-sided chambers and increases in volume of right-sided chambers consistent with the shunt flow but no change in RV systolic function compared with sham. Changes in cardiac structure/function were more favorable in responders compared with nonresponders treated with the shunt, supporting the previously identified responder group hypothesis...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 17. doi: 10.1001/jamacardio.2024.0520. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Although the results of A Study to Evaluate the Corvia Medical Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients with Heart Failure (REDUCE LAP-HF II) trial were neutral overall, atrial shunt therapy demonstrated potential efficacy in responders (no latent pulmonary vascular disease and no cardiac rhythm management device). Post hoc analyses were conducted to evaluate the effect of shunt vs sham stratified by responder status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the effect of atrial shunt vs sham control on cardiac structure/function in the overall study and stratified by responder status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a sham-controlled randomized clinical trial of an atrial shunt device in heart failure with preserved ejection fraction (HFpEF)/HF with mildly reduced EF (HFmrEF). Trial participants with evaluable echocardiography scans were recruited from 89 international medical centers. Data were analyzed from April 2023 to January 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Atrial shunt device or sham control.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME MEASURES: Changes in echocardiographic measures from baseline to 1, 6, 12, and 24 months after index procedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The modified intention-to-treat analysis of the REDUCE LAP-HF II trial included 621 randomized patients (median [IQR] age, 72.0 [66.0-77.0] years; 382 female [61.5%]; shunt arm, 309 [49.8%]; sham control arm, 312 [50.2%]). Through 24 months, 212 of 217 patients (98%) in the shunt arm with evaluable echocardiograms had patent shunts. In the overall trial population, the shunt reduced left ventricular (LV) end-diastolic volume (mean difference, -5.65 mL; P &lt;.001), left atrial (LA) minimal volume (mean difference, -2.8 mL; P =.01), and improved LV systolic tissue Doppler velocity (mean difference, 0.69 cm/s; P &lt;.001) and LA emptying fraction (mean difference, 1.88 percentage units; P =.02) compared with sham. Shunt treatment also increased right ventricular (RV; mean difference, 9.58 mL; P &lt;.001) and right atrial (RA; mean difference, 9.71 mL; P &lt;.001) volumes but had no effect on RV systolic function, pulmonary artery pressure, or RA pressure compared with sham. In the shunt arm, responders had smaller increases in RV end-diastolic volume (mean difference, 5.71 mL vs 15.18 mL; interaction P =.01), RV end-systolic volume (mean difference, 1.58 mL vs 7.89 mL; interaction P =.002), and RV/LV ratio (mean difference, 0.07 vs 0.20; interaction P &lt;.001) and larger increases in transmitral A wave velocity (mean difference, 5.08 cm/s vs -1.97 cm/s; interaction P =.02) compared with nonresponders randomized to the shunt, suggesting greater ability to accommodate shunted blood through the pulmonary circulation enabling LA unloading.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this post hoc analysis of the REDUCE LAP-HF II trial, over 2 years of follow-up, atrial shunting led to reverse remodeling of left-sided chambers and increases in volume of right-sided chambers consistent with the shunt flow but no change in RV systolic function compared with sham. Changes in cardiac structure/function were more favorable in responders compared with nonresponders treated with the shunt, supporting the previously identified responder group hypothesis and mechanism, although further evaluation with longer follow-up is needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03088033.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630494/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38630494</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0520>10.1001/jamacardio.2024.0520</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630494</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ravi B Patel</dc:creator>
<dc:creator>Frank E Silvestry</dc:creator>
<dc:creator>Jan Komtebedde</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Gerd Hasenfuß</dc:creator>
<dc:creator>Sheldon E Litwin</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Matthew J Price</dc:creator>
<dc:creator>Rami Kawash</dc:creator>
<dc:creator>Scott L Hummel</dc:creator>
<dc:creator>Donald E Cutlip</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Andreas J Rieth</dc:creator>
<dc:creator>Scott McKenzie</dc:creator>
<dc:creator>Heiko Bugger</dc:creator>
<dc:creator>Jeremy A Mazurek</dc:creator>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:creator>Marc Vanderheyden</dc:creator>
<dc:creator>Bonnie Ky</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38630494</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0520</dc:identifier>
</item>
<item>
<title>Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630489/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among birisk patients with ACS who completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months before randomization, an extended 9-month clopidogrel monotherapy regimen was superior to continuing DAPT with clopidogrel in reducing clinically relevant bleeding without increasing ischemic events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 17. doi: 10.1001/jamacardio.2024.0534. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Purinergic receptor P2Y12 (P2Y12) inhibitor monotherapy after a certain period of dual antiplatelet therapy (DAPT) may be an attractive option of maintenance antiplatelet treatment for patients undergoing percutaneous coronary intervention (PCI) who are at both high bleeding and ischemic risk (birisk).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing DAPT with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in birisk patients with acute coronary syndromes (ACS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, double-blind, placebo-controlled, randomized clinical trial including birisk patients with ACS who had completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months at 101 China centers between February 2018 and December 2020. Study data were analyzed from April 2023 to May 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized either to clopidogrel plus placebo or clopidogrel plus aspirin for an additional 9 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding 9 months after randomization. The key secondary end point was major adverse cardiac and cerebral events (MACCE; the composite of all-cause death, myocardial infarction, stroke or clinically driven revascularization). The primary end point was tested for superiority, and the MACCE end point was tested for sequential noninferiority and superiority.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 7758 patients (mean [SD] age, 64.8 [9.0] years; 4575 male [59.0%]) were included in this study. The primary end point of BARC types 2, 3, or 5 bleeding occurred in 95 of 3873 patients (2.5%) assigned to clopidogrel plus placebo and 127 of 3885 patients (3.3%) assigned to clopidogrel plus aspirin (hazard ratio [HR], 0.75; 95% CI, 0.57-0.97; difference, -0.8%; 95% CI, -1.6% to -0.1%; P = .03). The incidence of MACCE was 2.6% (101 of 3873 patients) in the clopidogrel plus placebo group and 3.5% (136 of 3885 patients) in the clopidogrel plus aspirin group (HR, 0.74; 95% CI, 0.57-0.96; difference, -0.9%; 95% CI, -1.7% to -0.1%; P &lt; .001 for noninferiority; P = .02 for superiority).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among birisk patients with ACS who completed 9 to 12 months of DAPT after drug-eluting stent implantation and were free from adverse events for at least 6 months before randomization, an extended 9-month clopidogrel monotherapy regimen was superior to continuing DAPT with clopidogrel in reducing clinically relevant bleeding without increasing ischemic events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03431142.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630489/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38630489</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0534>10.1001/jamacardio.2024.0534</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630489</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Yi Li</dc:creator>
<dc:creator>Jing Li</dc:creator>
<dc:creator>Bin Wang</dc:creator>
<dc:creator>Quanmin Jing</dc:creator>
<dc:creator>Yujie Zeng</dc:creator>
<dc:creator>Aijie Hou</dc:creator>
<dc:creator>Zhifang Wang</dc:creator>
<dc:creator>Aijun Liu</dc:creator>
<dc:creator>Jinliang Zhang</dc:creator>
<dc:creator>Yaojun Zhang</dc:creator>
<dc:creator>Ping Zhang</dc:creator>
<dc:creator>Daming Jiang</dc:creator>
<dc:creator>Bin Liu</dc:creator>
<dc:creator>Jiamao Fan</dc:creator>
<dc:creator>Jun Zhang</dc:creator>
<dc:creator>Li Li</dc:creator>
<dc:creator>Guohai Su</dc:creator>
<dc:creator>Ming Yang</dc:creator>
<dc:creator>Weihong Jiang</dc:creator>
<dc:creator>Peng Qu</dc:creator>
<dc:creator>Hesong Zeng</dc:creator>
<dc:creator>Lu Li</dc:creator>
<dc:creator>Miaohan Qiu</dc:creator>
<dc:creator>Leisheng Ru</dc:creator>
<dc:creator>Shaoliang Chen</dc:creator>
<dc:creator>Yujie Zhou</dc:creator>
<dc:creator>Shubin Qiao</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Yaling Han</dc:creator>
<dc:creator>OPT-BIRISK Investigators</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38630489</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0534</dc:identifier>
</item>
<item>
<title>Clopidogrel Monotherapy for Double-Risk Acute Coronary Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38630487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 17. doi: 10.1001/jamacardio.2024.0547. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38630487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38630487</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0547>10.1001/jamacardio.2024.0547</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38630487</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Antonio Landi</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Clopidogrel Monotherapy for Double-Risk Acute Coronary Syndrome</dc:title>
<dc:identifier>pmid:38630487</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0547</dc:identifier>
</item>
<item>
<title>Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via Histone Lactylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38629274/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Taken together, our findings reveal that NR4A3-mediated histone lactylation is a novel metabolome-epigenome signaling cascade mechanism that participates in the pathogenesis of medial arterial calcification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 17. doi: 10.1161/CIRCRESAHA.123.323699. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Medial arterial calcification is a chronic systemic vascular disorder distinct from atherosclerosis and is commonly observed in patients with chronic kidney disease, diabetes, and aging individuals. We previously showed that NR4A3 (nuclear receptor subfamily 4 group A member 3), an orphan nuclear receptor, is a key regulator in apo (apolipoprotein) A-IV-induced atherosclerosis progression; however, its role in vascular calcification is poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We generated NR4A3<sup>-/-</sup> mice and 2 different types of medial arterial calcification models to investigate the biological roles of NR4A3 in vascular calcification. RNA-seq was performed to determine the transcriptional profile of NR4A3<sup>-/-</sup> vascular smooth muscle cells under β-glycerophosphate treatment. We integrated CUT&amp;Tag analysis and RNA-seq data to further investigate the gene regulatory mechanisms of NR4A3 in arterial calcification and target genes regulated by histone lactylation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: NR4A3 expression was upregulated in calcified aortic tissues from chronic kidney disease mice, 1,25(OH)<sub>2</sub>VitD<sub>3</sub> overload-induced mice, and human calcified aorta. NR4A3 deficiency preserved the vascular smooth muscle cell contractile phenotype, inhibited osteoblast differentiation-related gene expression, and reduced calcium deposition in the vasculature. Further, NR4A3 deficiency lowered the glycolytic rate and lactate production during the calcification process and decreased histone lactylation. Mechanistic studies further showed that NR4A3 enhanced glycolysis activity by directly binding to the promoter regions of the 2 glycolysis genes <i>ALDOA</i> and <i>PFKL</i> and driving their transcriptional initiation. Furthermore, histone lactylation promoted medial calcification both in vivo and in vitro. NR4A3 deficiency inhibited the transcription activation and expression of Phospho1 (phosphatase orphan 1). Consistently, pharmacological inhibition of Phospho1-attenuated calcium deposition in NR4A3-overexpressed vascular smooth muscle cells, whereas overexpression of Phospho1 reversed the anticalcific effect of NR4A3 deficiency in vascular smooth muscle cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Taken together, our findings reveal that NR4A3-mediated histone lactylation is a novel metabolome-epigenome signaling cascade mechanism that participates in the pathogenesis of medial arterial calcification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38629274/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38629274</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323699>10.1161/CIRCRESAHA.123.323699</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38629274</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Wenqi Ma</dc:creator>
<dc:creator>Kangni Jia</dc:creator>
<dc:creator>Haomai Cheng</dc:creator>
<dc:creator>Hong Xu</dc:creator>
<dc:creator>Zhigang Li</dc:creator>
<dc:creator>Hang Zhang</dc:creator>
<dc:creator>Hongyang Xie</dc:creator>
<dc:creator>Lingfang Zhuang</dc:creator>
<dc:creator>Ziyang Wang</dc:creator>
<dc:creator>Yuke Cui</dc:creator>
<dc:creator>Hang Sun</dc:creator>
<dc:creator>Lei Yi</dc:creator>
<dc:creator>Zhiyong Chen</dc:creator>
<dc:creator>Shengzhong Duan</dc:creator>
<dc:creator>Motoaki Sano</dc:creator>
<dc:creator>Keiichi Fukuda</dc:creator>
<dc:creator>Lin Lu</dc:creator>
<dc:creator>Fei Gao</dc:creator>
<dc:creator>Ruiyan Zhang</dc:creator>
<dc:creator>Xiaoxiang Yan</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Orphan Nuclear Receptor NR4A3 Promotes Vascular Calcification via Histone Lactylation</dc:title>
<dc:identifier>pmid:38629274</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323699</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in arrhythmias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38628042/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 17:ehae189. doi: 10.1093/eurheartj/ehae189. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38628042/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38628042</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae189>10.1093/eurheartj/ehae189</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38628042</guid>
<pubDate>Wed, 17 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Harry J G M Crijns</dc:creator>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:creator>Prashantan Sanders</dc:creator>
<dc:date>2024-04-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in arrhythmias</dc:title>
<dc:identifier>pmid:38628042</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae189</dc:identifier>
</item>
<item>
<title>Gut bacteria can break down cholesterol</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38627565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Apr 16. doi: 10.1038/s41569-024-01026-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38627565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38627565</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01026-w>10.1038/s41569-024-01026-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38627565</guid>
<pubDate>Tue, 16 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2024-04-16</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Gut bacteria can break down cholesterol</dc:title>
<dc:identifier>pmid:38627565</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01026-w</dc:identifier>
</item>
<item>
<title>Creating connections when we talk about science</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38626771/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>For Cell's 50^(th) anniversary Focus on Immunology, scientific editor Cheri Sirois asked science communicator Liz Neeley, founding partner of Liminal and cofounder of Solving for Science, to discuss strategies for tackling technical complexity and for engaging effectively with broad audiences. A lightly edited transcript of their conversation is shared here.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 6:S0092-8674(24)00359-3. doi: 10.1016/j.cell.2024.03.043. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">For Cell's 50<sup>th</sup> anniversary Focus on Immunology, scientific editor Cheri Sirois asked science communicator Liz Neeley, founding partner of Liminal and cofounder of Solving for Science, to discuss strategies for tackling technical complexity and for engaging effectively with broad audiences. A lightly edited transcript of their conversation is shared here.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38626771/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38626771</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.043>10.1016/j.cell.2024.03.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38626771</guid>
<pubDate>Tue, 16 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Creating connections when we talk about science</dc:title>
<dc:identifier>pmid:38626771</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.043</dc:identifier>
</item>
<item>
<title>Global, site-resolved analysis of ubiquitylation occupancy and turnover rate reveals systems properties</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38626770/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>Ubiquitylation regulates most proteins and biological processes in a eukaryotic cell. However, the site-specific occupancy (stoichiometry) and turnover rate of ubiquitylation have not been quantified. Here we present an integrated picture of the global ubiquitylation site occupancy and half-life. Ubiquitylation site occupancy spans over four orders of magnitude, but the median ubiquitylation site occupancy is three orders of magnitude lower than that of phosphorylation. The occupancy, turnover...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 8:S0092-8674(24)00315-5. doi: 10.1016/j.cell.2024.03.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ubiquitylation regulates most proteins and biological processes in a eukaryotic cell. However, the site-specific occupancy (stoichiometry) and turnover rate of ubiquitylation have not been quantified. Here we present an integrated picture of the global ubiquitylation site occupancy and half-life. Ubiquitylation site occupancy spans over four orders of magnitude, but the median ubiquitylation site occupancy is three orders of magnitude lower than that of phosphorylation. The occupancy, turnover rate, and regulation of sites by proteasome inhibitors are strongly interrelated, and these attributes distinguish sites involved in proteasomal degradation and cellular signaling. Sites in structured protein regions exhibit longer half-lives and stronger upregulation by proteasome inhibitors than sites in unstructured regions. Importantly, we discovered a surveillance mechanism that rapidly and site-indiscriminately deubiquitylates all ubiquitin-specific E1 and E2 enzymes, protecting them against accumulation of bystander ubiquitylation. The work provides a systems-scale, quantitative view of ubiquitylation properties and reveals general principles of ubiquitylation-dependent governance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38626770/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38626770</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.024>10.1016/j.cell.2024.03.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38626770</guid>
<pubDate>Tue, 16 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Gabriela Prus</dc:creator>
<dc:creator>Shankha Satpathy</dc:creator>
<dc:creator>Brian T Weinert</dc:creator>
<dc:creator>Takeo Narita</dc:creator>
<dc:creator>Chunaram Choudhary</dc:creator>
<dc:date>2024-04-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Global, site-resolved analysis of ubiquitylation occupancy and turnover rate reveals systems properties</dc:title>
<dc:identifier>pmid:38626770</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.024</dc:identifier>
</item>
<item>
<title>Body mass index, waist circumference, and mortality in subjects older than 80 years: a Mendelian randomization study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38626306/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among the oldest-old, opposite causal associations of BMI and WC with mortality were observed, and a body figure with higher BMI and lower WC could substantially decrease the mortality risk. Guidelines for the weight management should be cautiously designed and implemented among the oldest-old people, considering distinct roles of BMI and WC.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 16:ehae206. doi: 10.1093/eurheartj/ehae206. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Emerging evidence has raised an obesity paradox in observational studies of body mass index (BMI) and health among the oldest-old (aged ≥80 years), as an inverse relationship of BMI with mortality was reported. This study was to investigate the causal associations of BMI, waist circumference (WC), or both with mortality in the oldest-old people in China.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 5306 community-based oldest-old (mean age 90.6 years) were enrolled in the Chinese Longitudinal Healthy Longevity Survey (CLHLS) between 1998 and 2018. Genetic risk scores were constructed from 58 single-nucleotide polymorphisms (SNPs) associated with BMI and 49 SNPs associated with WC to subsequently derive causal estimates for Mendelian randomization (MR) models. One-sample linear MR along with non-linear MR analyses were performed to explore the associations of genetically predicted BMI, WC, and their joint effect with all-cause mortality, cardiovascular disease (CVD) mortality, and non-CVD mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During 24 337 person-years of follow-up, 3766 deaths were documented. In observational analyses, higher BMI and WC were both associated with decreased mortality risk [hazard ratio (HR) 0.963, 95% confidence interval (CI) 0.955-0.971 for a 1-kg/m2 increment of BMI and HR 0.971 (95% CI 0.950-0.993) for each 5 cm increase of WC]. Linear MR models indicated that each 1 kg/m2 increase in genetically predicted BMI was monotonically associated with a 4.5% decrease in all-cause mortality risk [HR 0.955 (95% CI 0.928-0.983)]. Non-linear curves showed the lowest mortality risk at the BMI of around 28.0 kg/m2, suggesting that optimal BMI for the oldest-old may be around overweight or mild obesity. Positive monotonic causal associations were observed between WC and all-cause mortality [HR 1.108 (95% CI 1.036-1.185) per 5 cm increase], CVD mortality [HR 1.193 (95% CI 1.064-1.337)], and non-CVD mortality [HR 1.110 (95% CI 1.016-1.212)]. The joint effect analyses indicated that the lowest risk was observed among those with higher BMI and lower WC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among the oldest-old, opposite causal associations of BMI and WC with mortality were observed, and a body figure with higher BMI and lower WC could substantially decrease the mortality risk. Guidelines for the weight management should be cautiously designed and implemented among the oldest-old people, considering distinct roles of BMI and WC.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38626306/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38626306</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae206>10.1093/eurheartj/ehae206</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38626306</guid>
<pubDate>Tue, 16 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Yuebin Lv</dc:creator>
<dc:creator>Yue Zhang</dc:creator>
<dc:creator>Xinwei Li</dc:creator>
<dc:creator>Xiang Gao</dc:creator>
<dc:creator>Yongyong Ren</dc:creator>
<dc:creator>Luojia Deng</dc:creator>
<dc:creator>Lanjing Xu</dc:creator>
<dc:creator>Jinhui Zhou</dc:creator>
<dc:creator>Bing Wu</dc:creator>
<dc:creator>Yuan Wei</dc:creator>
<dc:creator>Xingyao Cui</dc:creator>
<dc:creator>Zinan Xu</dc:creator>
<dc:creator>Yanbo Guo</dc:creator>
<dc:creator>Yidan Qiu</dc:creator>
<dc:creator>Lihong Ye</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:creator>Jun Wang</dc:creator>
<dc:creator>Chenfeng Li</dc:creator>
<dc:creator>Yufei Luo</dc:creator>
<dc:creator>Zhaoxue Yin</dc:creator>
<dc:creator>Chen Mao</dc:creator>
<dc:creator>Qiong Yu</dc:creator>
<dc:creator>Hui Lu</dc:creator>
<dc:creator>Virginia Byers Kraus</dc:creator>
<dc:creator>Yi Zeng</dc:creator>
<dc:creator>Shilu Tong</dc:creator>
<dc:creator>Xiaoming Shi</dc:creator>
<dc:date>2024-04-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Body mass index, waist circumference, and mortality in subjects older than 80 years: a Mendelian randomization study</dc:title>
<dc:identifier>pmid:38626306</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae206</dc:identifier>
</item>
<item>
<title>Correction to: Anthracycline therapy induces an early decline of cardiac contractility with transient edema in low risk patients with breast cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38626300/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 16:ehae185. doi: 10.1093/eurheartj/ehae185. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38626300/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38626300</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae185>10.1093/eurheartj/ehae185</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38626300</guid>
<pubDate>Tue, 16 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Anthracycline therapy induces an early decline of cardiac contractility with transient edema in low risk patients with breast cancer</dc:title>
<dc:identifier>pmid:38626300</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae185</dc:identifier>
</item>
<item>
<title>Immunoproteasomal Processing of IsoLG-Adducted Proteins Is Essential for Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38623763/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These studies define a previously unknown role of the immunoproteasome in DCs and ECs in CD8^(+) T cell activation. The immunoproteasome in DCs and ECs is critical for isoLG-adduct presentation to CD8^(+) T cells, and in the endothelium, this guides homing and infiltration of T cells to specific tissues.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Apr 16. doi: 10.1161/CIRCRESAHA.124.324068. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertension is characterized by CD8<sup>+</sup> T cell activation and infiltration into peripheral tissues. CD8<sup>+</sup> T cell activation requires proteasomal processing of antigenic proteins. It has become clear that isoLG (isolevuglandin)-adduced peptides are antigenic in hypertension; however, IsoLGs inhibit the constitutive proteasome. We hypothesized that immunoproteasomal processing of isoLG-adducts is essential for CD8<sup>+</sup> T cell activation and inflammation in hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: IsoLG adduct processing was studied in murine dendritic cells (DCs), endothelial cells (ECs), and B8 fibroblasts. The role of the proteasome and the immunoproteasome in Ang II (angiotensin II)-induced hypertension was studied in <i>C57BL/6</i> mice treated with bortezomib or the immunoproteasome inhibitor PR957 and by studying mice lacking 3 critical immunoproteasome subunits (triple knockout mouse). We also examined hypertension in mice lacking the critical immunoproteasome subunit LMP7 specifically in either DCs or ECs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that oxidant stress increases the presence of isoLG adducts within MHC-I (class I major histocompatibility complex), and immunoproteasome overexpression augments this. Pharmacological or genetic inhibition of the immunoproteasome attenuated hypertension and tissue inflammation. Conditional deletion of LMP7 in either DCs or ECs attenuated hypertension and vascular inflammation. Finally, we defined the role of the innate immune receptors stimulator of interferon genes and TLR7/8 (toll-like receptor 7/8) as drivers of LMP7 expression in ECs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These studies define a previously unknown role of the immunoproteasome in DCs and ECs in CD8<sup>+</sup> T cell activation. The immunoproteasome in DCs and ECs is critical for isoLG-adduct presentation to CD8<sup>+</sup> T cells, and in the endothelium, this guides homing and infiltration of T cells to specific tissues.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38623763/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38623763</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324068>10.1161/CIRCRESAHA.124.324068</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38623763</guid>
<pubDate>Tue, 16 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Néstor de la Visitación</dc:creator>
<dc:creator>Wei Chen</dc:creator>
<dc:creator>Jaya Krishnan</dc:creator>
<dc:creator>Justin P Van Beusecum</dc:creator>
<dc:creator>Venkataraman Amarnath</dc:creator>
<dc:creator>Elizabeth M Hennen</dc:creator>
<dc:creator>Shilin Zhao</dc:creator>
<dc:creator>Mohammad Saleem</dc:creator>
<dc:creator>Mingfang Ao</dc:creator>
<dc:creator>Sergey I Dikalov</dc:creator>
<dc:creator>Anna E Dikalova</dc:creator>
<dc:creator>David G Harrison</dc:creator>
<dc:creator>David M Patrick</dc:creator>
<dc:date>2024-04-16</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Immunoproteasomal Processing of IsoLG-Adducted Proteins Is Essential for Hypertension</dc:title>
<dc:identifier>pmid:38623763</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324068</dc:identifier>
</item>
<item>
<title>Systolic Blood Pressure and Survival to Very Old Age: Results From the Women's Health Initiative</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38623761/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: For women >;65 years of age with low cardiovascular disease and other chronic disease risk, an SBP level &lt;130 mm Hg was found to be associated with longevity. These findings reinforce current guidelines targeting an SBP target &lt;130 mm Hg in older women.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 16. doi: 10.1161/CIRCULATIONAHA.123.067302. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The relationship between systolic blood pressure (SBP) and longevity is not fully understood. We aimed to determine which SBP levels in women ≥65 years of age with or without blood pressure medication were associated with the highest probability of surviving to 90 years of age.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study population consisted of 16570 participants enrolled in the Women's Health Initiative who were eligible to survive to 90 years of age by February 28, 2020, without a history of cardiovascular disease, diabetes, or cancer. Blood pressure was measured at baseline (1993 through 1998) and then annually through 2005. The outcome was defined as survival to 90 years of age with follow-up. Absolute probabilities of surviving to 90 years of age were estimated for all combinations of SBP and age using generalized additive logistic regression modeling. The SBP that maximized survival was estimated for each age, and a 95% CI was generated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During a median follow-up of 19.8 years, 9723 of 16<b> </b>570 women (59%) survived to 90 years of age. Women with an SBP between 110 and 130 mm Hg at attained ages of 65, 70, 75, and 80 years had a 38% (95% CI, 34%-48%), 54% (52%-56%), 66% (64%-67%), or 75% (73%-78%) absolute probability to survive to 90 years of age, respectively. The probability of surviving to 90 years of age was lower for greater SBP levels. Women at the attained age of 80 years with 0%, 20%, 40%, 60%, 80%, or 100% time in therapeutic range (defined as an SBP between 110 and 130 mm Hg) had a 66% (64%-69%), 68% (67%-70%), 71% (69%-72%), 73% (71%-74%), 75% (72%-77%), or 77% (74%-79%) absolute survival probability to 90 years of age.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For women >;65 years of age with low cardiovascular disease and other chronic disease risk, an SBP level &lt;130 mm Hg was found to be associated with longevity. These findings reinforce current guidelines targeting an SBP target &lt;130 mm Hg in older women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38623761/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38623761</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067302>10.1161/CIRCULATIONAHA.123.067302</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38623761</guid>
<pubDate>Tue, 16 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Bernhard Haring</dc:creator>
<dc:creator>Chris A Andrews</dc:creator>
<dc:creator>Kathleen Hovey</dc:creator>
<dc:creator>Aladdin H Shadyab</dc:creator>
<dc:creator>Andrea LaCroix</dc:creator>
<dc:creator>Lisa Warsinger Martin</dc:creator>
<dc:creator>Milagros C Rosal</dc:creator>
<dc:creator>Lewis H Kuller</dc:creator>
<dc:creator>Elena Salmoirago-Blotcher</dc:creator>
<dc:creator>Nazmus Saquib</dc:creator>
<dc:creator>Patrick Koo</dc:creator>
<dc:creator>Deepika Laddu</dc:creator>
<dc:creator>Marcia L Stefanick</dc:creator>
<dc:creator>JoAnn E Manson</dc:creator>
<dc:creator>Sylvia Wassertheil-Smoller</dc:creator>
<dc:creator>Michael J LaMonte</dc:creator>
<dc:date>2024-04-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Systolic Blood Pressure and Survival to Very Old Age: Results From the Women's Health Initiative</dc:title>
<dc:identifier>pmid:38623761</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067302</dc:identifier>
</item>
<item>
<title>Home-based fitness training: chicken soup for the ACHD soul?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38621021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 15:ehae142. doi: 10.1093/eurheartj/ehae142. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38621021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38621021</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae142>10.1093/eurheartj/ehae142</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38621021</guid>
<pubDate>Mon, 15 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Keri M Shafer</dc:creator>
<dc:creator>Anne Marie Valente</dc:creator>
<dc:date>2024-04-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Home-based fitness training: chicken soup for the ACHD soul?</dc:title>
<dc:identifier>pmid:38621021</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae142</dc:identifier>
</item>
<item>
<title>Correction to: 2023 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38620091/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 16;149(16):e1128. doi: 10.1161/CIR.0000000000001242. Epub 2024 Apr 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38620091/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38620091</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001242>10.1161/CIR.0000000000001242</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38620091</guid>
<pubDate>Mon, 15 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2023 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations: Summary From the Basic Life Support; Advanced Life Support; Pediatric Life Support; Neonatal Life Support; Education, Implementation, and Teams; and First Aid Task Forces</dc:title>
<dc:identifier>pmid:38620091</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001242</dc:identifier>
</item>
<item>
<title>Health-Related Quality of Life Instruments in Chronic Limb-Threatening Ischemia: Evolution of Defining Quality of Life in a Complex Disease State</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38620090/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 16;149(16):1254-1257. doi: 10.1161/CIRCULATIONAHA.123.067812. Epub 2024 Apr 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38620090/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38620090</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067812>10.1161/CIRCULATIONAHA.123.067812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38620090</guid>
<pubDate>Mon, 15 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer A Rymer</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:date>2024-04-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Health-Related Quality of Life Instruments in Chronic Limb-Threatening Ischemia: Evolution of Defining Quality of Life in a Complex Disease State</dc:title>
<dc:identifier>pmid:38620090</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067812</dc:identifier>
</item>
<item>
<title>Correction to: Cytokine mRNA Degradation in Cardiomyocytes Restrains Sterile Inflammation in Pressure-Overloaded Hearts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38620089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 16;149(16):e1131. doi: 10.1161/CIR.0000000000001248. Epub 2024 Apr 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38620089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38620089</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001248>10.1161/CIR.0000000000001248</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38620089</guid>
<pubDate>Mon, 15 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Cytokine mRNA Degradation in Cardiomyocytes Restrains Sterile Inflammation in Pressure-Overloaded Hearts</dc:title>
<dc:identifier>pmid:38620089</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001248</dc:identifier>
</item>
<item>
<title>Correction to: Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38620088/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 16;149(16):e1130. doi: 10.1161/CIR.0000000000001249. Epub 2024 Apr 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38620088/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38620088</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001249>10.1161/CIR.0000000000001249</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38620088</guid>
<pubDate>Mon, 15 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure</dc:title>
<dc:identifier>pmid:38620088</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001249</dc:identifier>
</item>
<item>
<title>Correction to: Toward Heart-Healthy and Sustainable Cities: A Policy Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38620087/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 16;149(16):e1129. doi: 10.1161/CIR.0000000000001244. Epub 2024 Apr 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38620087/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38620087</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001244>10.1161/CIR.0000000000001244</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38620087</guid>
<pubDate>Mon, 15 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Toward Heart-Healthy and Sustainable Cities: A Policy Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38620087</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001244</dc:identifier>
</item>
<item>
<title>The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38620086/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 16;149(16):1315-1318. doi: 10.1161/CIRCULATIONAHA.123.066933. Epub 2024 Apr 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38620086/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38620086</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066933>10.1161/CIRCULATIONAHA.123.066933</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38620086</guid>
<pubDate>Mon, 15 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Deborah M Siegal</dc:creator>
<dc:creator>Nauzer Forbes</dc:creator>
<dc:creator>John Eikelboom</dc:creator>
<dc:creator>Jan Beyer-Westendorf</dc:creator>
<dc:creator>Alexander T Cohen</dc:creator>
<dc:creator>Lizhen Xu</dc:creator>
<dc:creator>Stuart J Connolly</dc:creator>
<dc:creator>Mark Crowther</dc:creator>
<dc:date>2024-04-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis</dc:title>
<dc:identifier>pmid:38620086</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066933</dc:identifier>
</item>
<item>
<title>Artificial Intelligence and Machine Learning in Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38620085/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240417141106&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 16;149(16):1235-1237. doi: 10.1161/CIRCULATIONAHA.123.065469. Epub 2024 Apr 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38620085/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240417141106&v=2.18.0.post9+e462414">38620085</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065469>10.1161/CIRCULATIONAHA.123.065469</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38620085</guid>
<pubDate>Mon, 15 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Rahul C Deo</dc:creator>
<dc:date>2024-04-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Artificial Intelligence and Machine Learning in Cardiology</dc:title>
<dc:identifier>pmid:38620085</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065469</dc:identifier>
</item>





























</channel>
</rss>